Drug therapy for chronic heart failure due to left ventricular systolic dysfunction: A review. III. Angiotensin-converting enzyme inhibitors;Terapêutica farmacológica da insuficiência cardíaca crónica por disfunção sistólica do ventrículo esquerdo. III. Inibidores da enzima de conversão da angiotensina

Revista Portuguesa de Cardiologia

Volumn 27, Issue 9, 2008, Pages 1169-1187

  Ascenção, Raquel ^a   Fortuna, Philip ^a   Reis, Inês ^a   Carneiro, António Vaz ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; RAMIPRIL; TRANDOLAPRIL;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COUGHING; CREATININE BLOOD LEVEL; DIZZINESS; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE OVERLOAD; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOTENSION; IMPOTENCE; KIDNEY DISEASE; MORBIDITY; MORTALITY; SIDE EFFECT; UREMIA;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; HEART FAILURE; HUMANS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 57349181247     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med 2008;358:1370-80.
2. Colucci WS. Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: mechanisms of action. UpToDate 2007:15,3.
3. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
4. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1005;273:1450-6.
5. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen G, Ball S, Pogue J, Moyé L, Braunwald E, for the ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575-81.
6. Abdulla J, Pogue J, Abildstrom SZ, Kober L, Christensen E, Pfeffer MA, Yusuf S, Torp-Pedersen C. Effect of angiotensin-converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction - a meta-analysis. Eur J Heart Fail 2006;8:90-6.
7. Shekelle PG, Rich MW, Morton SC, Atkinson SW, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg B, Heidenreich PA, Knabel T, Konstam MA, Steimle A, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender and diabetic status. Journal of American College of Cardiology 2003;41:1529-38.
8. Packer M, Poole-Wilson PA, Armstrong PW, Cleland J, Horowitz JD, Massie BM, Rydén L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-8.
9. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
10. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
11. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, Aliot E, Persson S, Camm AJ, for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.
12. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
13. Pfeffer MA, Braunwald E, Moyé L, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-77.
14. Kleber FX, Niemoller L, Doering W. Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial. Br Heart J 1992;67:289-96.
15. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure - results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
16. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin- converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
17. Agusti A, Bonet S, Arnau JM, Vidal X, Laporte JR. Adverse effects of ACE inhibitors in patients with chronic heart failure and/or ventricular dysfunction. Drug Safety 2003;26:895-908.
18. Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 2001;38:421-8.
19. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
20. Eccles M, Freemantle N, Mason J. North of England evidence based development project: guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure. BMJ 1998;316:1369-75.